Product Description
YY162 attenuated the increase in reactive oxygen species (ROS) and decrease in BDNF levels induced by Aroclor1254 in SH-SY5Y neuroblastoma cells. YY162 significantly attenuated Aroclor1254-induced ADHD-like behavior and oxidative stress in ICR mice. Furthermore, YY162 attenuated reductions in p-TrkB, BDNF, dopamine transporter (DAT) and norepinephrine transporter (NET) expression.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24394491/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yuyu Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Psychotic Disorders|Attention Deficit Disorder with Hyperactivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ADHD | P3 |
Completed |
Psychotic Disorders|Attention Deficit Disorder with Hyperactivity |
2012-08-01 |
2019-03-19 |
Treatments |
|
| yuyu | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity|Psychotic Disorders |
2010-04-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|